ENOV · Enovis CORP

Track ENOV — free

$20.71 +0.84 (+4.23%)

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$1.15B

57.67M

Volume · Oct 20 549.95K Avg daily vol (3M) 1.48M

Up next

Next earnings call

Nov 5, 2026 Scheduled · in 2 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

$2.30B

Trailing 12 months

Net income (TTM)

−$1.10B

Trailing 12 months

Revenue growth YoY

+3.2%

Year over year

Operating margin

-45.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

5.6%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$1.27B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.8%

Year over year · more shares

Price change (1Y)

-36.8%

Trailing year

Short interest

18.3%

Latest settlement · 5.8 days to cover

View all 122 metrics

Quarterly results

Revenue Net income Net loss

▲21% $505.22M −$31.52M '24 Q3 ▲23.3% $560.98M −$703.34M '24 Q4* ▲8.2% $558.83M −$55.97M '25 Q1 ▲7.5% $564.54M −$36.74M '25 Q2 ▲8.6% $548.91M −$571.15M '25 Q3 ▲2.6% $575.76M −$520.59M '25 Q4* ▲5.4% $589.15M −$8.76M '26 Q1 LATEST ▲3.2% $582.78M −$1.19M '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. Enovis reported Q2 sales of $583M (5% organic), 14% underlying adjusted EPS growth to $0.90, and 70bps underlying adjusted EBITDA margin expansion to 17.9%, while reaffirming full-year 2026 guidance despite $10M of incremental inflationary headwinds and softer Western Europe and Middle East markets.

Bullish

+ Recon grew 8% reported / 6% organic in Q2 with U.S. hips and knees up 8%, and Arvis moved into full U.S. commercial launch with strong early surgeon feedback.
+ Adjusted gross margin expanded ~120bps underlying to 62% and adjusted EBITDA margin improved 70bps underlying to 17.9%, with management calling out a multi-year cadence of margin expansion.
+ Adjusted EPS of $0.90 represented 14% underlying growth in Q2 and 12% earnings growth through the first half.
+ Company reaffirmed full-year 2026 guidance for revenue ($2.31-2.37B, 4-6% organic), adjusted EBITDA ($425-435M), adjusted EPS ($3.52-$3.73), and >25% free cash flow conversion.

Bearish

− Q2 growth faced a ~100bps headwind from the Middle East conflict and softer Western European markets (France, Spain, Italy), with management guiding to a more seasonally soft Q3 than in prior years.
− Full-year 2026 will absorb approximately $10M of incremental inflationary pressure from raw materials, freight and distribution costs tied to the Middle East conflict, offsetting the $8M tariff refund benefit.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 18.4 · elevated Equity put/call 0.55

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −15%

below

Price vs 50-day avg −4%

below

RSI (14) 56

neutral

MACD trend Positive

52-week position 16%

mid-range

Momentum

relative strength

Weak

1-month return +10%

trailing

6-month return −15%

trailing

YTD return −25%

this year

Relative strength −23%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $21 › 200d $23 — 200d above 50d

Institutional flow Distributing

24 of 256 funds reported for Sep 30 · net -2.4M sh shares · +1 new

Insider flow Accumulating

Net +$449.6K over 90 days · 0% sells

Short interest Rising

18.31% of float · ▲ +11.4% MoM · 5.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

256 holders — near 3-yr low, contrarian setup

Squeeze score 74

high risk · 0–100

Fundamentals

Strong

Revenue growth +7%

Y/Y

Gross margin 60%

expanding

EPS growth −39%

Y/Y

Free cash flow $19.9M

Buyback $100.0M

remaining

Balance sheet $1.3B

net debt

Quant / Vol

risk profile

Very High

Volatility 63%

annualized · 1-yr

Max drawdown −47%

past year

ATR 4.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 2 of last 3

Latest guidance · from the 8-K filed Aug 6, 2026

full year 2026

Adjusted EBITDA Non-GAAP Maintained $425M – $435M

May 7, 2026 $425M – $435M Aug 6, 2026 $425M – $435M

full-year 2026

Adjusted earnings per share Non-GAAP Maintained $3.52 – $3.73

May 7, 2026 $3.52 – $3.73 Aug 6, 2026 $3.52 – $3.73

Full year 2026

Free cash flow conversion Non-GAAP at least 25%

Prior guidance period ended · from the 8-K filed Nov 6, 2025

Revenue · full-year 2025 $2.24B – $2.27B

Adjusted EBITDA · full-year 2025 $395M – $405M

Adjusted earnings per share · full-year 2025 $3.10 – $3.25

Guided vs delivered · last 3 settled

Revenue full-year 2025

guided $2.24B – $2.27B

guided $2.24B – $2.27B $2.25B In line

Full-year revenue Full-year 2024

guided $2.08B – $2.13B

guided $2.08B – $2.13B $2.11B In line

Earnings per share third quarter

guided $0.50 – $0.55

guided $0.50 – $0.55 $0.49 Miss −6.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−15% Bearish

Price vs 50-day avg

−4% Neutral

RSI (14)

56 Neutral

MACD trend

Positive Bullish

52-week position

16% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $21 › 200d $23 — 200d above 50d

Institutional flow Distributing

24 of 256 funds reported for Sep 30 · net -2.4M sh shares · +1 new

Insider flow Accumulating

Net +$449.6K over 90 days · 0% sells

Short interest Rising

18.31% of float · ▲ +11.4% MoM · 5.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

256 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

Range low $17 Now $20 · 16% Range high $33

vs 200-day avg -15% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA (non-GAAP) non-GAAP	$207.9M	Six Months Ended July 3, 2026	—
Adjusted EBITDA (non-GAAP) - Prevention & Recovery non-GAAP	50.33M	Three Months Ended July 3, 2026 filing	—
Adjusted EBITDA (non-GAAP) - Prevention & Recovery segment non-GAAP	$50.3M	Three Months Ended July 3, 2026 filing	—
Adjusted EBITDA (non-GAAP) - Reconstructive non-GAAP	53.99M	Three Months Ended July 3, 2026 filing	—
Adjusted EBITDA (non-GAAP) - Total non-GAAP	104.32M	Three Months Ended July 3, 2026 filing	—
Adjusted EBITDA margin non-GAAP	17.9%	Second Quarter 2026	—
Adjusted EBITDA margin (non-GAAP) non-GAAP	17.7%	Six Months Ended July 3, 2026	—
Adjusted EBITDA margin (non-GAAP) - Prevention & Recovery segment non-GAAP	17.5%	Three Months Ended July 3, 2026 filing	—
Adjusted gross profit (Non-GAAP) non-GAAP	$725.9M	Six Months Ended July 3, 2026	—
Adjusted gross profit margin (Non-GAAP) non-GAAP	61.9%	Six Months Ended July 3, 2026	—
Adjusted net income from continuing operations non-GAAP	$52.2M	Second Quarter 2026	—
Adjusted net income from continuing operations (non-GAAP) non-GAAP	$103.8M	Six Months Ended July 3, 2026	—
Adjusted net income margin from continuing operations non-GAAP	8.9%	Six Months Ended July 3, 2026	—
Adjusted net income per share - diluted from continuing operations non-GAAP	$0.9	Second Quarter 2026	—
Adjusted net income per share - diluted from continuing operations (non-GAAP) non-GAAP	$1.79	Six Months Ended July 3, 2026	—
Capital expenditures - Prevention & Recovery	7.11M	Three Months Ended July 3, 2026 filing	—
Capital expenditures - Reconstructive	36.79M	Three Months Ended July 3, 2026 filing	—
Total capital expenditures	43.9M	Three Months Ended July 3, 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ENOV Enovis CORP this stock	$1.15B	-25.4%	+6.7%	—	18.3%
ABT Abbott Laboratories	$179.20B	-16.9%	+5.7%	33.3	0.8%
MDT Medtronic plc	$118.67B	-3.4%	+8.4%	22.9	3.1%
SYK Stryker Corp	$114.28B	-15.2%	+11.2%	30.9	1.5%
BSX Boston Scientific Corp	$65.16B	-52.8%	+12.5%	18.2	2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

253

% held: 122.0%
Reported: 24 of 256
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

304

View

Short & Settlement

Short Interest Rising

Shares short

10.6M

Days to cover: 5.8d
Change: +1.1M sh

View

Short Volume

Short vol %

78%

As of: Oct 19, 2026

Short Total

View

Fails to Deliver

FTD shares

2.0K

Value: $37.5K
As of: Sep 28, 2026

View

Off-Exchange

Off-exchange %

46.7%

Week of: Sep 14, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$449.6K

Buyers / Sellers: 2 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$2.2B

Net income (FY): $-1.2B
EPS diluted: $-20.75

View

Buybacks

Authorized

$100.0M

Remaining: $100.0M

Spent Remaining

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 8, 2026
This year: 12

View

Proposed Sales

Value

$34.9K

Shares: 645
Filed: Jun 2, 2023

View

Earnings & Events

Webcasts Upcoming

Next webcast

Nov 5, 2026

Last webcast: Sep 8, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
ENOV	+8.9%	+10.1%	-15.1%	+8.8%	-25.4%
SPY	-1.5%	-0.9%	+7.7%	+0.5%	+12.4%
vs SPY	+10.4%	+11.1%	-22.8%	+8.3%	-37.8%

Capital returns

Buyback program · as of Jul 3, 2026

Authorized

$100.00M

Spent (derived)

Remaining

$100.00M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1420800 CUSIP 194014502 13F (30d) 22 filings 22 filers Visit website Investor relations

ENOV · Enovis CORP

Price & Indicators

Up next

Metrics snapshot

Quarterly results

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns